MXPA03005099A - Formulacion de liberacion extendida oral de gepirona. - Google Patents
Formulacion de liberacion extendida oral de gepirona.Info
- Publication number
- MXPA03005099A MXPA03005099A MXPA03005099A MXPA03005099A MXPA03005099A MX PA03005099 A MXPA03005099 A MX PA03005099A MX PA03005099 A MXPA03005099 A MX PA03005099A MX PA03005099 A MXPA03005099 A MX PA03005099A MX PA03005099 A MXPA03005099 A MX PA03005099A
- Authority
- MX
- Mexico
- Prior art keywords
- gepirone
- release formulation
- extended release
- oral extended
- oral
- Prior art date
Links
- 238000013265 extended release Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 title 1
- 229960000647 gepirone Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00204388 | 2000-12-08 | ||
| PCT/EP2001/014189 WO2002045753A2 (en) | 2000-12-08 | 2001-11-30 | Oral extended release formulation of gepirone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03005099A true MXPA03005099A (es) | 2004-02-12 |
Family
ID=8172397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03005099A MXPA03005099A (es) | 2000-12-08 | 2001-11-30 | Formulacion de liberacion extendida oral de gepirona. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1343504A2 (cs) |
| JP (1) | JP2004517083A (cs) |
| KR (1) | KR20040018314A (cs) |
| CN (1) | CN1479620A (cs) |
| AR (1) | AR031461A1 (cs) |
| AU (1) | AU2002226371A1 (cs) |
| BR (1) | BR0115976A (cs) |
| CA (1) | CA2436692A1 (cs) |
| CZ (1) | CZ20031589A3 (cs) |
| EC (1) | ECSP034627A (cs) |
| HU (1) | HUP0401021A2 (cs) |
| IL (1) | IL155855A0 (cs) |
| MX (1) | MXPA03005099A (cs) |
| NO (1) | NO20032581L (cs) |
| PL (1) | PL362445A1 (cs) |
| RU (1) | RU2003120446A (cs) |
| SK (1) | SK6942003A3 (cs) |
| WO (1) | WO2002045753A2 (cs) |
| ZA (1) | ZA200303915B (cs) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060134193A1 (en) * | 2002-09-24 | 2006-06-22 | Pieter De Haan | Method to improve pharmaceutical tablets having a matrix of cellulose ether |
| BRPI0419179A (pt) * | 2004-11-05 | 2007-12-18 | Fabre Kramer Pharmaceuticals I | formulação de alta dosagem de liberação prolongada de gepirona |
| WO2019023250A1 (en) * | 2017-07-26 | 2019-01-31 | Abbott Laboratories | NUTRITIONAL TABLETS AND METHODS OF MAKING THE SAME |
| CN109745323A (zh) * | 2017-11-01 | 2019-05-14 | 四川科瑞德制药股份有限公司 | 氮哌酮类化合物提高副交感神经活性的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
-
2001
- 2001-11-30 WO PCT/EP2001/014189 patent/WO2002045753A2/en not_active Ceased
- 2001-11-30 BR BR0115976-3A patent/BR0115976A/pt not_active Application Discontinuation
- 2001-11-30 PL PL01362445A patent/PL362445A1/xx not_active Application Discontinuation
- 2001-11-30 RU RU2003120446/15A patent/RU2003120446A/ru not_active Application Discontinuation
- 2001-11-30 SK SK694-2003A patent/SK6942003A3/sk unknown
- 2001-11-30 HU HU0401021A patent/HUP0401021A2/hu unknown
- 2001-11-30 MX MXPA03005099A patent/MXPA03005099A/es unknown
- 2001-11-30 JP JP2002547535A patent/JP2004517083A/ja not_active Withdrawn
- 2001-11-30 CA CA002436692A patent/CA2436692A1/en not_active Abandoned
- 2001-11-30 KR KR10-2003-7007555A patent/KR20040018314A/ko not_active Withdrawn
- 2001-11-30 AU AU2002226371A patent/AU2002226371A1/en not_active Abandoned
- 2001-11-30 CN CNA018201792A patent/CN1479620A/zh active Pending
- 2001-11-30 IL IL15585501A patent/IL155855A0/xx unknown
- 2001-11-30 CZ CZ20031589A patent/CZ20031589A3/cs unknown
- 2001-11-30 EP EP01995688A patent/EP1343504A2/en not_active Withdrawn
- 2001-12-07 AR ARP010105683A patent/AR031461A1/es not_active Application Discontinuation
-
2003
- 2003-05-20 ZA ZA200303915A patent/ZA200303915B/en unknown
- 2003-05-28 EC EC2003004627A patent/ECSP034627A/es unknown
- 2003-06-06 NO NO20032581A patent/NO20032581L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002045753A3 (en) | 2002-08-29 |
| IL155855A0 (en) | 2003-12-23 |
| RU2003120446A (ru) | 2005-02-20 |
| CA2436692A1 (en) | 2002-06-13 |
| HUP0401021A2 (hu) | 2004-09-28 |
| EP1343504A2 (en) | 2003-09-17 |
| ZA200303915B (en) | 2004-08-20 |
| ECSP034627A (es) | 2004-09-28 |
| BR0115976A (pt) | 2003-12-30 |
| NO20032581D0 (no) | 2003-06-06 |
| AR031461A1 (es) | 2003-09-24 |
| WO2002045753A2 (en) | 2002-06-13 |
| CN1479620A (zh) | 2004-03-03 |
| CZ20031589A3 (cs) | 2003-11-12 |
| KR20040018314A (ko) | 2004-03-03 |
| SK6942003A3 (en) | 2003-10-07 |
| AU2002226371A1 (en) | 2002-06-18 |
| NO20032581L (no) | 2003-06-06 |
| PL362445A1 (en) | 2004-11-02 |
| JP2004517083A (ja) | 2004-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG23943A (en) | Flash-melt oral dosage formulation | |
| AU9208601A (en) | Delayed release pharmaceutical formulations | |
| ZA200007715B (en) | Stable extended release oral dosage composition. | |
| ZA200007714B (en) | Extended release oral dosage composition. | |
| AU6089200A (en) | Rapid immediate release oral dosage form | |
| AU4009201A (en) | Sustained release ranolazine formulations | |
| MXPA03002569A (es) | Formulaciones de liberacion controlada para administracion oral. | |
| HUP0301177A3 (en) | Ion-strength independent sustained release pharmaceutical formulation | |
| AU2001248336A1 (en) | Controlled release oral solid forms containing mesalazine as active agent | |
| HUP0204417A3 (en) | Oral ciprofloxacin-composition of controlled release | |
| PL354075A1 (en) | Oral controlled release formulations | |
| HUP0401599A3 (en) | Extended release oral dosage form | |
| MXPA03005099A (es) | Formulacion de liberacion extendida oral de gepirona. | |
| EP1357898A4 (en) | ORAL DOSAGE FORM WITH ENHANCED REGULATED RELEASE | |
| AU2001241187A1 (en) | Sustained release oral preparations | |
| GB2363073B (en) | Oral rehydration formulation | |
| PL362244A1 (en) | Medicinal compositions | |
| AU2001293278A1 (en) | Tableted oral extended release dosage form | |
| ZA200105511B (en) | Oral solid pharmaceutical formulations with ph dependent multiphasic release | |
| HU0900677D0 (en) | Extended release oral dosage composition | |
| GB0011333D0 (en) | Controlled release formulations | |
| AUPQ780600A0 (en) | Modified release formulation | |
| SI1216032T1 (sl) | Oralne formulacije s kontroliranim sproščanjem | |
| GB0008029D0 (en) | New vaccine formulations | |
| GB0022027D0 (en) | Disfectant formulations |